Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)
17.20
+0.62 (3.74%)
Oct 21, 2026, 4:08 PM HKT
Shanghai Junshi Biosciences Employees
Shanghai Junshi Biosciences had 3,055 employees as of June 30, 2026. The number of employees increased by 152 or 5.24% since the number was reported on December 31, 2025. That makes Shanghai Junshi Biosciences the 7,865th largest employer in the world and 603rd in Hong Kong.
Employees
3,055
Change
152
Growth
5.24%
Revenue / Employee
1.14M HKD
Profits / Employee
-166.58K HKD
Market Cap
32.84B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 3,055 | 152 | 5.24% | 3,055 | 0 |
| Dec 31, 2025 | 2,903 | 325 | 12.61% | 2,903 | 0 |
| Dec 31, 2024 | 2,578 | 10 | 0.39% | 2,578 | 0 |
| Dec 31, 2023 | 2,568 | -393 | -13.27% | 2,568 | 0 |
| Dec 31, 2022 | 2,961 | 156 | 5.56% | 2,961 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
| Biocytogen Pharmaceuticals (Beijing) | 1,922 |
| Zai Lab | 1,784 |
| Keymed Biosciences | 1,768 |
| InnoCare Pharma | 1,388 |
Shanghai Junshi Biosciences News
- 1 month ago - Shanghai Junshi Biosciences Earnings release: H1 2026 - Filings
- 1 month ago - Shanghai Junshi Biosciences Slides: H1 2026 - Filings
- 1 month ago - Shanghai Junshi Biosciences Quarterly report: H1 2026 - Filings
- 3 months ago - Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLC - GlobeNewsWire
- 4 months ago - Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III NSCLC - GlobeNewsWire
- 5 months ago - Shanghai Junshi Biosciences Earnings release: Q1 2026 - Filings
- 6 months ago - Junshi Biosciences Presents Results from JS207 (PD-1/VEGF BsAb) Phase 2 Combo Studies and JS212 (EGFR/HER3 ADC) FIH Phase 1/2 Study at AACR 2026 - GlobeNewsWire
- 7 months ago - Junshi Biosciences Announces 2025 Full Year Financial Results and Provides Corporate Updates - GlobeNewsWire